Dako A/S (Acquired by Agilent Technologies, Inc.) to Collaborate With Pfizer Inc. on Companion Diagnostics
Published: Feb 12, 2013
GLOSTRUP, DENMARK--(Marketwire - February 12, 2013) - Dako, an Agilent Technologies company, announced today it has entered into a collaboration agreement with Pfizer in the field of companion diagnostics.
The agreement constitutes a legal framework for various collaboration projects between the two companies, covering research, development and commercialization as well as advisory services.
"We are extremely excited to partner with Pfizer, a company with such a global presence and reputation for market leadership," said Lars Holmkvist, CEO of Dako and senior vice president, Agilent. "This collaboration is testimony to the level of expertise and service Dako is committed to delivering to our partners in companion diagnostics."
Companion diagnostics are seen as the cornerstones of precision medicine. They provide a way to improve patient care and reduce health-care costs by matching specific therapies to the individuals most likely to benefit from them, since all patients do not respond in the same way.
"This partnership with Dako will support Pfizer's companion diagnostics efforts, an important component of our growing Precision Medicine capabilities," said John Hubbard, senior vice president, Development Operations at Pfizer. "Precision Medicine R&D is designed to advance more targeted therapies for patients, improve efficacy, safety and success rates, and expedite development."
Financial terms of the agreement were not disclosed.
Today's news follows an earlier announcement from Dako introducing a master framework agreement between Dako and Eli Lilly and Company, which focuses on developing novel companion diagnostics for Eli Lilly's oncology pipeline.
About Dako - An Agilent Technologies Company
Dako is relentless in its commitment to fighting cancer together with customers and strategic partners-because patients' lives depend on companies continuing to bring scientific advancement to the diagnostic and therapeutic fields.
Dako, based in Denmark, is a global leader in tissue-based cancer diagnostics. Hospital and research laboratories worldwide use Dako's reagents, instruments, software and expertise to make accurate diagnoses and determine the most effective treatment for cancer patients. Dako, with 1,200 employees, operates in more than 100 countries. Dako became part of Agilent Technologies on June 21, 2012. Information about Dako is available at www.dako.com.
About Agilent Technologies
Agilent Technologies Inc. (NYSE: A) is the world's premier measurement company and a technology leader in chemical analysis, life sciences, diagnostics, electronics and communications. The company's 20,500 employees serve customers in more than 100 countries. Agilent had revenues of $6.9 billion in fiscal 2012. Information about Agilent is available at www.agilent.com.
This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Dako Denmark A/S via Thomson Reuters ONE
Maia Fredtoft Sochting
+45 25 46 10 83
Dako Denmark A/S